Details for Patent: 12,097,202
✉ Email this page to a colleague
Which drugs does patent 12,097,202 protect, and when does it expire?
Patent 12,097,202 protects REZUROCK and is included in one NDA.
This patent has two patent family members in two countries.
Drugs Protected by US Patent 12,097,202
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kadmon Pharms Llc | REZUROCK | belumosudil mesylate | TABLET;ORAL | 214783-001 | Jul 16, 2021 | RX | Yes | Yes | 12,097,202 | ⤷ Subscribe | TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CHRONIC GVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH A GRADE 3 INFECTION ADVERSE REACTION | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,097,202
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 3178096 | ⤷ Subscribe | |||
| World Intellectual Property Organization (WIPO) | 2024015067 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
